-+ 0.00%
-+ 0.00%
-+ 0.00%

Iksuda Reports 80% Clinical Benefit Rate for IKS014 in HER2+ Oesophageal Cancer Phase 1 Trial

Reuters·01/06/2026 11:07:36

Please log in to view news